Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Synthesis and Regulation of Thyroid Hormones

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

BIoecology of Oncideres cervina Thomson (Coleoptera: Cerambycidae) on Persea americana Mill. (Lauraceae).

Brazilian journal of biology = Revista brasleira de biologia·2023

Same author

Investigation of Cellular Interactions of Lipid-Structured Nanoparticles With Oral Mucosal Epithelial Cells.

Frontiers in molecular biosciences·2022

Same author

Spatial distribution and sample size to estimate Lycosa erythrognatha (Araneae: Lycosidae) population density overwintering.

Brazilian journal of biology = Revista brasleira de biologia·2020

Same author

Relationship Between Stink Bug Populations in Winter Shelters and Atmospheric Variables in Soybean Growing Areas in Southern Brazil.

Neotropical entomology·2020

Same author

A novel hybrid nanofibrous strategy to target progenitor cells for cost-effective in situ angiogenesis.

Journal of materials chemistry. B·2020

Same author

Forage system is the key driver of mountain milk specificity.

Journal of dairy science·2019

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Decrease in dipeptidyl peptidase IV activity is linked to the efficacy of differentiating compounds in follicular

E Fröhlich¹, E Engel, R Wahl

¹Internal Medicine, Department IV, University of Tübingen, Germany.

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme

|March 18, 2011

Summary

Differentiating agents like retinol may enhance radioiodine therapy for thyroid cancer by decreasing dipeptidyl peptidase IV (DPP IV) activity. This decrease correlates with increased iodide uptake and cell differentiation in cancer models.

Related Experiment Videos

Last Updated: Jun 3, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Area of Science:

Oncology
Endocrinology
Biochemistry

Background:

Metastatic differentiated thyroid carcinoma (DTC) treatment involves surgery and radioiodine therapy.
Differentiating agents offer potential to improve radioiodine therapy efficacy.
Thyroid carcinoma malignancy is linked to dipeptidyl peptidase IV (DPP IV) and aminopeptidase N activities.

Purpose of the Study:

Evaluate DPP IV, aminopeptidase N, and dipeptidyl peptidase II activities in human follicular thyroid carcinoma (FTC) cell lines.
Investigate the effects of differentiating agents (retinol, apicidine, lovastatin) on these activities and cellular functions.
Determine the role of DPP IV activity in thyroid cancer cell differentiation and radioiodine uptake.

Main Methods:

Cultured human FTC cell lines (FTC 138, FTC 238).
Treated cells with retinol, apicidine, and lovastatin.
Assayed DPP IV, aminopeptidase N, and dipeptidyl peptidase II activities.
Measured thyroglobulin, sodium-iodide symporter (NIS) expression, iodide uptake, and thymidine uptake.

Main Results:

FTC cell lines exhibited high DPP IV and low aminopeptidase N activity.
Retinol treatment increased thyroglobulin and NIS expression, iodide uptake, and cell differentiation.
Retinol, apicidine, and lovastatin treatments decreased DPP IV activity.
Decreased DPP IV activity correlated with increased iodide uptake.

Conclusions:

A decrease in DPP IV activity is linked to the differentiating action of agents in thyroid cancer.
Differentiating agents enhance thyroid cancer cell differentiation and iodide uptake.
Targeting DPP IV activity may represent a strategy to improve radioiodine therapy for DTC.